Costs of Integrated Mass Drug Administration for Neglected Tropical Diseases in Haiti

التفاصيل البيبلوغرافية
العنوان: Costs of Integrated Mass Drug Administration for Neglected Tropical Diseases in Haiti
المؤلفون: Margaret Baker, Ann S. Goldman, Mary Linehan, Jean-Francois Vely, Molly Brady, Roland Oscard, Abdel N. Direny, Luccene Desir
المصدر: The American Journal of Tropical Medicine and Hygiene. 85:826-833
بيانات النشر: American Society of Tropical Medicine and Hygiene, 2011.
سنة النشر: 2011
مصطلحات موضوعية: medicine.medical_specialty, Population, Helminthiasis, Albendazole, Diethylcarbamazine, Elephantiasis, Filarial, Drug Therapy, Virology, Environmental health, Prevalence, Humans, Medicine, Mass drug administration, education, health care economics and organizations, Lymphatic filariasis, Anthelmintics, education.field_of_study, business.industry, Public health, Neglected Diseases, Tropical disease, Articles, medicine.disease, Haiti, Surgery, Infectious Diseases, Costs and Cost Analysis, Neglected tropical diseases, Parasitology, business, medicine.drug
الوصف: We conducted a cost analysis of Haiti's Ministry of Public Health and Population neglected tropical disease program, Projet des Maladies Tropicales Negligées and collected data for 9 of 55 communes participating in the May 2008–April 2009 mass drug administration (MDA). The Projet des Maladies Tropicales Negligées Program partnered with IMA World Health and Hôpital Ste. Croix to implement MDA for treatment of lymphatic filariasis and soil-transmitted helminthiasis by using once a year treatment with albendazole and diethylcarbamazine in a population of approximately 8 million persons. Methods included analyzing partner financial records and conducting retrospective surveys of personnel. In the nine communes, 633,261 persons were treated at a cost of U.S. $0.64 per person, which included the cost of donated drugs, and at a cost of U.S. $0.42 per person treated, when excluding donated drug costs. The MDA for lymphatic filariasis in Haiti began in 2000, with the treatment of 105,750 persons at a cost per person of U.S. $2.23. The decrease in cost per person treated is the result of cumulative implementation experience and economies of scale.
تدمد: 1476-1645
0002-9637
DOI: 10.4269/ajtmh.2011.10-0635
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26778e0d7120c637c5bbbce27366dc8e
https://doi.org/10.4269/ajtmh.2011.10-0635
Rights: OPEN
رقم الانضمام: edsair.doi.dedup.....26778e0d7120c637c5bbbce27366dc8e
قاعدة البيانات: OpenAIRE
الوصف
تدمد:14761645
00029637
DOI:10.4269/ajtmh.2011.10-0635